Aardvark Therapeutics reports financial results in the first quarter of 2025 and offers business highlights – Tradingview News

• Phase 3 Hero study with ARD-101 for the treatment of hyperphagia in connection with Prader-Willi syndrome (PWS); Data recording that is expected in early 2026
• $ 151.3 million in cash, cash equivalents and short -term investments support the forecast operations in 2027

San Diego, May 14, 2025 (Globe Newswire) – Aardvark Therapeutics, Inc. (Aardvark) AardA biopharmaceutical company in the clinical stage focused on the development of new, small molecules therapeutic agents for the activation of innate homeostatic ways of treating metabolic diseases, which today proved to be available for the first quarter on March 31, 2025.

“We believe that there is an important, unused opportunity to aim against anti-hunger signal transmission for the treatment of rare metabolic diseases and obesity. Our main candidate ARD-101 should address hunger by reducing the discomfort of the fasting without the desire of food or inducing food,” Tien Lee, Md, Founding and Chief Exexectation Officer Officer of Noardvark. “The Phase 3 hero study by ARD-101 in PWS shows our commitment to satisfy non-covered needs in this community.”

Summary of business complaints

• In February 2025, Aardvark successfully completed the first IPO (IPO) and collected a gross proceeds of 97.9 million US dollars. After deducting discounts, commissions and providers of drawings, the company received a net proceeds of around $ 87.5 million. Aardvark's share began to act on February 13, 2025 under the “Aard” symbol.

In the first quarter of 2025, select financial information

• Cash position: By March 31, 2025, Aardvark had cash, cash equivalent and short -term investments of $ 151.3 million, including the net proceeds from the IPO in February 2025. Due to the current operational plans, Aardvark is of the opinion that the existing cash, cash level and short -term investments, together with the conditions, is sufficient, the IPO Sufficient to project.
• F&E editions: The research and development costs amounted to March 31, 2025 and 2024, $ 7.8 million and USD 1.2 million. The increase of $ 6.6 million for March 31, 2025 ended in increased development costs, which are mainly associated with ARD-101 and an increase in the expenditure of the staff.
• G&A editions: The general and administrative expenses for the quarter, which ended on March 31, 2025 and 2024, were $ 2.7 million and $ 0.9 million. The increase in USD 1.9 million for the quarter ending on March 31, 2025 was mainly from the increase in professional fees, institutions and other and personnel -related costs, some of which were based on the starting company as public companies.
• Net lust: The net loss was $ 9.3 million and USD 2.2 million for March 31, 2025 and 2024.

Via Aardvark Therapeutics, Inc.

Aardvark is a biopharmaceutical company in the clinical stage that develops new, small molecule therapeutic agents to suppress hunger for the treatment of PWS and metabolic diseases. The recognition of hunger (the discomfort of having not eaten lately) is a pronounced neuronal signal path that is separated from the appetite (search for reward, desirability of food). Our programs examine therapeutic applications in hungry-associated indications and potential complementary uses with anti-appetite therapies. Our lead connection, Oral ARD-101, is located in clinical phase 3 for the treatment of hyperphagia in connection with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also examined in hypothalamic obesity. Aardvark also develops ARD-201, a fixed dosage combination of ARD-101 with a DPP-4 inhibitor, with the aim of using some of the restrictions on the currently marketed GLP-1 therapies for the treatment of obesity and obesity conditions. For more information, see AardvingtapieTics.com.

Predicted statements

Statements in this press release on future expectations, plans and prospects as well as other statements to be asked that are not historical facts can show “future -oriented statements”. These statements include statements about statements: Aardvarks future results of operations and financial positions, business strategy, product candidates, ongoing clinical studies, planned clinical studies, expected times for data crossing and reporting on Topline results, expected cash -landing, probability of success and plans and goals for future operations. The words, without restriction, “foreseen”, “faith”, “further”, “,” appreciate “,” expect “,” intend “,” may “,” plan “,” potential “,” forecast “,” project “,” goal “,” want “,” dignity “,” to identify future -oriented future -oriented statements. Actual results can differ from those that are given by such future -oriented statements as a result of various important factors, including: uncertainties in connection with potential delays at the beginning, enrollment and conclusion; Manufacture, shipping as well as clinical and preclinical studies; Commission to be submitted. When evaluating Aardvark's business and prospects, these risks and uncertainties should be carefully taken into account. All future -oriented statements contained in this press release are based on the current expectations of the Aardvark management team and only speak here on the date, and Aardvark expressly refuses to update a future -oriented explanation, be it based on new information, future events or others as a result.

contact:

Carolyn Hawley, Inizio Evoke Comms

(619) 849-5382

Carolyn.hawley@inizioevoke.com